Ubiquitin Isopeptidase Inhibitor I, G5
Based on 7 publication(s) in Google Scholar
Ubiquitin Isopeptidase Inhibitor I, G5 (NSC 144303) is an apoptosome-independent caspase and apoptosis activator with IC50 values of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 108477-18-5
- Formula: C19H14N2O7S
- Molecular Weight:414.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ubiquitin Isopeptidase Inhibitor I, G5
More- Nat Commun. 2025 May 27;16(1):4887. [Abstract]
- Acta Pharm Sin B. 2022 Apr;12(4):1856-1870. [Abstract]
- J Exp Clin Cancer Res. 2023 Sep 4;42(1):228. [Abstract]
- J Pathol. 2026 Jun;269(2):197-209. [Abstract]
- J Inflamm Res. 2023 Feb 27:16:861-877. [Abstract]
- Exp Cell Res. 2021 Nov 15;408(2):112861. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 12;522(3):647-654. [Abstract]
Biological Activity
IC50: 1.76 μM (E1A cells), 1.6 μM (E1A/C9DN cells)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
33.23 μM
Compound: G5
|
Inhibition of recombinant human USP18 (16 to 372 aa) expressed in Sf9 cells using ISG15-AMC as substrate preincubated for 30 mins before substrate addition measured after 60 mins by fluorescence assay
Inhibition of recombinant human USP18 (16 to 372 aa) expressed in Sf9 cells using ISG15-AMC as substrate preincubated for 30 mins before substrate addition measured after 60 mins by fluorescence assay
|
[PMID: 25639862] |
| U-87MG ATCC | IC50 |
0.77 μM
Compound: G5
|
Cytotoxicity against human U87MG cells after 48 hrs by resazurin assay
Cytotoxicity against human U87MG cells after 48 hrs by resazurin assay
|
[PMID: 25639862] |
G5 is capable of activating an apoptosome-independent apoptotic pathway. It targets the ubiquitinproteasome system by inhibiting the ubiquitin isopeptidases. G5 induces a rather unique apoptotic pathway, which includes a Bcl-2-dependent but apoptosome-independent mitochondrial pathway with upregulation of the BH3-only protein Noxa, stabilization of the inhibitor of apoptosis antagonist Smac, but also the involvement of the death receptor pathway. G5 is a potent apoptotic inducer showing IC50s of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 108477-18-5
-
Appearance Solid
-
Molecular Weight 414.39
-
Formula C19H14N2O7S
-
Color Light yellow to yellow
-
SMILES
O=C(/C(C1)=C/C2=CC=C([N+]([O-])=O)C=C2)/C(CS1(=O)=O)=C/C3=CC=C([N+]([O-])=O)C=C3
-
Synonyms
NSC144303
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly. [Abstract]2025 May 27;16(1):4887. PMID: 40425567 -
Acta Pharm Sin B
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RAR α and eradicates acute promyelocytic leukemia cells. [Abstract]2022 Apr;12(4):1856-1870. PMID: 35847510 -
J Exp Clin Cancer Res
Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. [Abstract]2023 Sep 4;42(1):228. PMID: 37667382 -
J Pathol
Neutrophil extracellular traps aggravate lung injury by inducing pyroptosis of alveolar macrophages. [Abstract]2026 Jun;269(2):197-209. PMID: 41823322 -
J Inflamm Res
Neutrophil Extracellular Traps Induce Alveolar Macrophage Pyroptosis by Regulating NLRP3 Deubiquitination, Aggravating the Development of Septic Lung Injury. [Abstract]2023 Feb 27:16:861-877. PMID: 36876152 -
Exp Cell Res
SIRT3 mediates mitofusin 2 ubiquitination and degradation to suppress ischemia reperfusion-induced acute kidney injury. [Abstract]2021 Nov 15;408(2):112861. PMID: 34624325 -
Biochem Biophys Res Commun
The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson's disease models. [Abstract]2020 Feb 12;522(3):647-654. PMID: 31787240
Solvent & Solubility
DMSO : 25 mg/mL (60.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
THF : 3.44 mg/mL (8.30 mM; Need ultrasonic)
Acetone : 2.86 mg/mL (6.90 mM; Need ultrasonic)
Ethanol : < 1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (24.13 mM); Suspended solution; Need ultrasonic
Protocol
Different drug concentrations are used to determine the dose-response profile and to calculate the IC50 value. Cells are incubated with the required concentrations of the 57 compounds. After 24 or 48 hours of incubation, cell death is evaluated bytr ypan blue staining[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Acetone / THF / DMSO | 1 mM | 2.4132 mL | 12.0659 mL | 24.1319 mL | 60.3296 mL |
| 5 mM | 0.4826 mL | 2.4132 mL | 4.8264 mL | 12.0659 mL | |
| DMSO | 10 mM | 0.2413 mL | 1.2066 mL | 2.4132 mL | 6.0330 mL |
| 15 mM | 0.1609 mL | 0.8044 mL | 1.6088 mL | 4.0220 mL | |
| 20 mM | 0.1207 mL | 0.6033 mL | 1.2066 mL | 3.0165 mL | |
| 25 mM | 0.0965 mL | 0.4826 mL | 0.9653 mL | 2.4132 mL | |
| 30 mM | 0.0804 mL | 0.4022 mL | 0.8044 mL | 2.0110 mL | |
| 40 mM | 0.0603 mL | 0.3016 mL | 0.6033 mL | 1.5082 mL | |
| 50 mM | 0.0483 mL | 0.2413 mL | 0.4826 mL | 1.2066 mL | |
| 60 mM | 0.0402 mL | 0.2011 mL | 0.4022 mL | 1.0055 mL |
Ubiquitin Isopeptidase Inhibitor I, G5 Related Classifications
HY-100738 Related Classifications
Powered by Bioz